Quest Diagnostics Reports Third Quarter 2024 Financial Results; Updates Guidance for Full Year 2024
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Quest Diagnostics (DGX) PT Raised to $165 at Leerink Partners
October 23, 2024 6:05 AM EDTLeerink Partners analyst Michael Cherny raised the price target on Quest Diagnostics (NYSE: DGX) to $165.00 (from $160.00) while maintaining a Market Perform rating.
The analyst comments "Bottom Line: DGX was poised for a solid quarter given elevated utilization, even with several moving pieces hitting adjusted EBIT margins. The company delivered solid base business growth, and management continues to... More
